Resultados de la búsqueda 401-410 of 12120 for 力曼保養品好用嗎加:💗line:sammibaby💗瞭解更多👜感謝您對力曼的信任與支持！ 我們將秉持著一貫的品質和服務標準,為您帶來更多驚喜和滿意！👗连江县刮油最好的减肥方法🦆万华区韓國化妝品男士
This randomized phase II trial studies how well olaparib, cediranib maleate, and standard chemotherapy work in treating patients with small cell lung cancer.
This research is being done to evaluate the safety and tolerability of the new drug, axatilimab, in combination with olaparib (a standard of care treatment) ...
... standard of care chemotherapy in participants with previously untreated BRAF V600E-mutant metastatic colorectal cancer (mCRC). A Study to Evaluate the ...
The purpose of this study is to find out more about certain markers of immune suppression in people with kidney tumors (whether the tumors are benign or ...
The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard ... maintenance II, maintenance), with some patients randomized to ...
Most newly-diagnosed CLL patients have early-stage disease at the time of diagnosis and do not require treatment. Despite not needing therapy, these patients ...
Germline and somatic variants are changes in genes found using cancer genomic tests. Cancer genetic/genomic testing is a series of tests that find specific ...
standard surgery (ILND); B. neoadjuvant chemotherapy followed by standard ... standard of care (SoC), best supportive care (BSC)) on protocol survivor ...
Additionally, to find out how well patients with low risk rhabdomyosarcoma (LR-RMS) respond to standard chemotherapy when patients with VLR-RMS and patients ...
Rochester, Minn. The purpose of this study is to find out more about certain markers of immune suppression in people with kidney tumors (whether the tumors are ...
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?